# FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind by the Agency

https://accortoreg.com/news/fda-permits-marketing-of-e-cigarette-products-marking-first-authorization-of-its-kind-by-the-agency

> News summary of an FDA press announcement — useful for awareness of regulatory action but not a primary source; when citing details, link to and attribute the FDA press release (linked on the page). Treat claims as reporting of FDA decisions, not independent analysis.

## Summary

Accorto summarizes an FDA announcement that the agency has authorized the marketing of three Vuse Solo ENDS products submitted by R.J. Reynolds under the PMTA pathway and issued 10 marketing denial orders for certain flavored Vuse ENDS applications; the page links to the FDA as the source.

## Audience

Regulatory professionals and industry stakeholders (e.g., tobacco/ENDS manufacturers, compliance teams)

## Prompts this page answers

- What did the FDA authorize regarding Vuse Solo e-cigarette products under the PMTA pathway?
- Which Vuse products received FDA marketing authorization and which were denied?
- What postmarket restrictions did the FDA impose on the authorized Vuse Solo products?
- Where can I find the FDA's original press announcement about the PMTA decisions?

## Purpose

Inform readers (particularly regulatory stakeholders) about the FDA's recent PMTA decisions concerning Vuse Solo ENDS products and related enforcement actions.

## Highlights

- FDA authorized marketing of three Vuse Solo products (Vuse Solo Power Unit, Vuse Replacement Cartridge Original 4.8% G1, and Vuse Replacement Cartridge Original 4.8% G2) via the PMTA pathway.
- FDA issued 10 marketing denial orders for certain flavored ENDS products submitted under the Vuse Solo brand by R.J. Reynolds.
- Authorization was granted because submitted data indicated reduced exposure to harmful and potentially harmful constituents compared to combusted cigarettes and potential benefit for adult smokers who switch.
- Authorization includes strict postmarketing and advertising restrictions and reporting requirements to limit youth exposure.
- The page emphasizes that authorization does not mean the products are safe or "FDA approved"; all tobacco products are harmful and addictive.

## How to cite

Accorto Regulatory Solutions news post (links to FDA press announcement). Link the Accorto page and the FDA source linked within it.

## Publisher

**Accorto Regulatory Solutions** — Accorto Regulatory Solutions — consultancy website providing regulatory solutions; contact and address are listed on the page.

## Topics

- FDA PMTA
- e-cigarette authorization
- Vuse Solo
- R.J. Reynolds
- marketing denial orders
- youth tobacco risk

## Key entities

- **U.S. Food and Drug Administration (FDA)** (organization): Federal agency; source of the press announcement linked on the page. — https://www.fda.gov
- **R.J. Reynolds (RJR) Vapor Company** (organization): Manufacturer that submitted the PMTA for Vuse Solo products; named on the page.
- **Vuse Solo Power Unit** (product): One of the three Vuse Solo products the FDA authorized to market.
- **Vuse Replacement Cartridge Original 4.8% G1** (product): One of the three Vuse Solo products the FDA authorized to market.
- **Vuse Replacement Cartridge Original 4.8% G2** (product): One of the three Vuse Solo products the FDA authorized to market.
- **Accorto Regulatory Solutions** (organization): Publisher of the news post; consultancy offering regulatory solutions (contact and address listed). — https://accortoreg.com/

## Metadata

- Type: article